Article

Site-active steroid provides symptomatic relief for patients with dry eye disease

Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.

Miami-Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.

Dr. Beraja, a private practitioner in Miami, says he particularly likes to prescribe the topical corticosteroid in older patients who complain of dry eye and are not achieving adequate relief from artificial tears alone. Patients are instructed to use loteprednol etabonate 0.2% up to four times a day as needed.

"I like to use this agent as a first-line treatment before prescribing cyclosporine because I find it is helpful administered on a prn [pro rata nata, i.e., as needed] basis. Typically, patients will use the loteprednol etabonate 0.2% for several days if they are experiencing a flare of symptoms, but once they are more comfortable, they are able to resume treatment with artificial tears alone," Dr. Beraja said.

In addition, patients are examined for other treatable conditions that may be contributing to their dry eye problem, such as blepharitis.

"In those situations, I also address the underlying external disease, but I prescribe the loteprednol etabonate to gain acute symptomatic control and tell patients they may re-initiate the loteprednol as needed if their symptoms suddenly worsen," Dr. Beraja said.

He is very comfortable letting patients use loteprednol etabonate 0.2% at their own discretion because of its excellent safety profile. Although loteprednol etabonate is a structural analogue of prednisolone, unlike its parent molecule and other corticosteroids that are used in the eye, loteprednol features an ester group instead of a ketone at the C20 molecular position. As a result of that modification, loteprednol etabonate is a "site-active" steroid.

After it is placed into the eye, loteprednol etabonate exerts its anti-inflammatory effect, but then it is rapidly metabolized by local esterases into inactive metabolites.

"Some increases in IOP have been reported in clinical trials of loteprednol etabonate," Dr. Beraja said. "However, the rate of clinically significant increases in IOP was only 1% in patients treated with loteprednol etabonate 0.2%, which was identical to that associated with placebo, and I have not yet encountered any patients whose IOP increased in association with using this product.

"As a precaution, however, I do not prescribe loteprednol etabonate 0.2% to treat dry eye in any patients with a known diagnosis of glaucoma," Dr. Beraja said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.